https://www.selleckchem.com/pr....oducts/bgj398-nvp-bg
An investigational agent that inhibits RAD51-mediated homologous recombination DNA repair has shown preliminary signs of activity. In a phase I trial, CYT-0851 elicited three responses in patients with relapsed/refractory hematologic malignancies and advanced solid tumors and was associated with only mild side effects. Over 1 billion individuals worldwide experience some form of sleep apnoea, and this number is steadily rising. Obstructive sleep apnoea (OSA) can negatively influence one's quality of life and potentially increa

https://www.selleckchem.com/pr....oducts/Neratinib(HKI
while the inhibition of HOXA10 or HDAC1 represents a promising anti-tumor therapy target for LAD. One objective of the Belgian Rare Diseases plan is to improve patients' management using phenotypic tests and, more specifically, the access to those tests by identifying the biochemical analyses used for rare diseases, developing new financing conditions and establishing reference laboratories. A feasibility study was performed from May 2015 until August 2016 in order to select the financeable biochemical analyses, and, among th